A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer

C. N. Sternberg^*, F. Saad, J. N. Graff, A. Peer, U. N. Vaishampayan, E. Leung, E. Rosenbaum, H. Gurney, R. J. Epstein, I. D. Davis, B. Wu, L. Trandafir, V. J. Wagner, M. Hussain

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review